INTERLEUKIN LEVEL 17 AS A BIOMARKER IN IMPROVING TREATMENT OF LUNG TB BEFORE TREATMENT AND AFTER 2 MONTHS OF OAT TREATMENT

Abstract

Background Tuberculosis is an important public health problem in the world. Indonesia ranks third in the world after China and India. The cause of TB is Mikrobakterium tuberculosis. Interleukin 17 (IL-17) is a cytokine that plays an important role in the pathogenesis of TB. Therefore, this study examined serum IL-17 levels before treatment and after 2 months of OAT treatment to determine its relationship with sputum smear conversion and therapeutic success.

Aim Analyzing changes in IL-17 levels in smear positive pulmonary TB patients before treatment and after 2 months of receiving anti-tuberculosis drug treatment (OAT).

Method Observational research with a cohort - prospective data collection method. Thirty subjects with positive smear pulmonary TB were taken blood samples, before treatment and after 2 months of OAT treatment to assess changes in IL-17 levels

Results Of 30 patients with positive smear pulmonary TB disease, the IL value of 17 before receiving OAT treatment was 75.2 (11.3 - 281.0) and after 2 months of treatment decreased to 35.1 (4.7 - 141.2) with P <0.05. By using the Spearman correlation obtained a significant correlation between IL-17 levels before and after treatment (p <0.05) and r = 0.72,

Conclusion From the results of the study concluded that there were significant differences in IL-17 levels before and after two months of intensive phase treatment.